Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Microbot Medical ( (MBOT) ) is now available.
On October 6, 2025, Microbot Medical Inc. completed the third and final closing of its exercise of outstanding preferred investment options, resulting in gross proceeds of $2.8 million. This final closing is part of a series of exercises that began with a $25.2 million first closing and a $1.2 million second closing, with the potential for an additional $63 million if all short-term series J preferred investment options are fully exercised. The proceeds will support the development and commercialization of the LIBERTY® Robotic System and other corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
The most recent analyst rating on (MBOT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a breakthrough medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency, and provider safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Average Trading Volume: 4,165,674
Technical Sentiment Signal: Buy
Current Market Cap: $146.7M
Find detailed analytics on MBOT stock on TipRanks’ Stock Analysis page.